Hospira Launches Generic Oxaliplatin Injection
11 Agosto 2009 - 12:29PM
PR Newswire (US)
-- Key Cancer Drug Offered In Solution Form -- LAKE FOREST, Ill.,
Aug. 11 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the
world leader in generic injectable pharmaceuticals, today announced
U.S. Food and Drug Administration (FDA) approval and launch of
oxaliplatin injection in the United States. The medication is a
generic version of Sanofi-Aventis' Eloxatin , which posted 2008
U.S. sales of approximately $1.4 billion. Hospira's oxaliplatin
injection is one of the first generic versions of this drug to come
in solution form. The innovator drug is also in solution form.
Oxaliplatin injection, used in combination with infusional
5-fluorouracil/leucovorin, is indicated for adjuvant treatment of
Stage III colon cancer in patients who have undergone complete
resection of the primary tumor, and in the treatment of advanced
colorectal cancer. "Hospira's launch of oxaliplatin injection in
solution form gives our customers a generic alternative of this
critical medication in the formulation they seek," said Sue
Hazelwood, vice president and general manager, alternate site,
U.S., Hospira. "This is another example of Hospira's dedication to
providing high-quality products that will reduce costs in the
oncology space." Hospira will initially offer oxaliplatin injection
in 50 mg and 100 mg single-use vials. Hospira's specialty
injectable pharmaceuticals (SIP) offering includes approximately
200 generic injectable drugs in many dosages and formulations. In
addition, many of its products are available in popular
differentiated formats, several of which are proprietary, such as
its ADD-Vantage drug delivery system and iSecure prefilled
syringes. Therapeutic areas include anesthesia, anti-infectives,
analgesics, cardiovascular, oncology, emergency and other areas.
Hospira has approximately 25 generic drugs scheduled to launch in
various regions around the world in 2009 and 2010. About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication
delivery company dedicated to Advancing Wellness(TM). As the world
leader in specialty generic injectable pharmaceuticals, Hospira
offers one of the broadest portfolios of generic acute-care and
oncology injectables, as well as integrated infusion therapy and
medication management solutions. Through its products, Hospira
helps improve the safety, cost and productivity of patient care.
The company is headquartered in Lake Forest, Ill., and has more
than 14,000 employees. Learn more at http://www.hospira.com/.
Private Securities Litigation Reform Act of 1995 -- A Caution
Concerning Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including projections of
certain measures of Hospira's results of operations, projections of
certain charges and expenses, and other statements regarding
Hospira's goals and strategy. Hospira cautions that these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
indicated in the forward-looking statements. Economic, competitive,
governmental, technological and other factors that may affect
Hospira's operations and may cause actual results to be materially
different from expectations include the risks, uncertainties and
factors discussed under the headings "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" in Hospira's latest Annual Report on Form
10-K filed with the Securities and Exchange Commission, which is
incorporated by reference. Hospira undertakes no obligation to
release publicly any revisions to forward-looking statements as the
result of subsequent events or developments.
http://www.newscom.com/cgi-bin/prnh/20040503/HSPLOGO
http://photoarchive.ap.org/ DATASOURCE: Hospira, Inc. CONTACT:
Media, Dan Rosenberg, +1-224-212-3366, or Financial Community,
Karen King, +1-224-212-2711, both of Hospira, Inc. Web Site:
http://www.hospira.com/
Copyright